(RTTNews) - Kalaris Therapeutics, Inc. (KLRS), a biopharmaceutical company, Monday announced that it has appointed Matthew Gall, as its chief financial officer.
Most recently, Gall was the finance chief of iTeos Therapeutics, and prior to iTeos he held positions at Sarepta Therapeutics, Celgene Corporation, and Gilead Sciences across the finance and business development functions.
In pre-market activity, Kalaris shares are trading at $5.45, up 8.35% on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
